Acadia Pharmaceuticals (ACAD) said remlifanserin narrowly missed the primary endpoint of SAPS H+D with significance on the key secondary endpoint of CGI-S-ADP.

In comparable episodes, the immediate question is whether the company can argue a clinically meaningful benefit despite the primary miss, and whether the agency is willing to accept a secondary endpoint as the basis for approval or a supplemental indication. The distinction worth drawing is between a clean efficacy failure and a marginal miss with supportive secondary data: the former tends to close the program, the latter often leads to a regulatory dialogue, possible post-hoc analyses, or a request for additional data. The tell is whether management signals intent to file, seek a meeting, or run another study, and whether the endpoint miss was driven by assay sensitivity, placebo response, or a subgroup effect. Prior form for the sponsor in navigating mixed readouts, and the precedent of the specific indication, tend to matter more than the headline statistical result. The next steps are typically a regulatory update, investor call, and any disclosure of the full data set, which will determine whether the program survives or is wound down.